DukagjinBlakajMDPhD
Radiation Oncology • Columbus, OHCentral Nervous System Cancer, Head & Neck, Skin Cancer
Professor Vice Chair of Clinical Operations Director HN/Skull Base Division Lead Spine Oncology Radiation Oncology TheOhio State University College of Medicine
Dr. Blakaj is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
410 W 10th Ave
Columbus, OH 43210Phone+1 614-293-8000Fax+1 614-293-3465
Summary
- Dr. Dukagjin Blakaj is a radiation oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute, Ohio State University Wexner Medical Center, and Chillicothe Veterans Affairs Medical Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 15 years. He specializes in tumors of the skull base, spine disorders, and head and neck radiation oncology.
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Radiation Oncology, 2009 - 2013
Icahn School of Medicine at Mount Sinai/Beth IsraelInternship, Internal Medicine, 2008 - 2009
Albert Einstein College of MedicineClass of 2008
Wesleyan UniversityBA, MA, MB&B, 1995 - 1999
Certifications & Licensure
NY State Medical License 2009 - 2025
OH State Medical License 2013 - 2025- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer Start of enrollment: 2022 May 12
Roles: Principal Investigator, Contact
- Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) Start of enrollment: 2023 Mar 27
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 159 citationsReduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)Sue S. Yom, Pedro A. Torres-Saavedra, Jimmy J. Caudell, John Waldron, Maura L. Gillison
Journal of Clinical Oncology. 2021-01-28 - 742 citationsRadiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari
Lancet. 2019-01-05 - 11 citationsPREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiother...Marcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, Kyle Colvett, Vinita Takiar
International Journal of Radiation Oncology, Biology, Physics. 2023-07-01
Professional Memberships
- Member
- Member
Other Languages
- Albanian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
